Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Background: Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. // Methods: We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung's disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. // Findings: We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung's disease) from 264 hospitals (89 in high-income countries, 166 in middle-income countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in low-income countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. // Interpretation: Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between low-income, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

Global variation in anastomosis and end colostomy formation following left-sided colorectal resection

Background End colostomy rates following colorectal resection vary across institutions in high-income settings, being influenced by patient, disease, surgeon and system factors. This study aimed to assess global variation in end colostomy rates after left-sided colorectal resection. Methods This study comprised an analysis of GlobalSurg-1 and -2 international, prospective, observational cohort studies (2014, 2016), including consecutive adult patients undergoing elective or emergency left-sided colorectal resection within discrete 2-week windows. Countries were grouped into high-, middle- and low-income tertiles according to the United Nations Human Development Index (HDI). Factors associated with colostomy formation versus primary anastomosis were explored using a multilevel, multivariable logistic regression model. Results In total, 1635 patients from 242 hospitals in 57 countries undergoing left-sided colorectal resection were included: 113 (6·9 per cent) from low-HDI, 254 (15·5 per cent) from middle-HDI and 1268 (77·6 per cent) from high-HDI countries. There was a higher proportion of patients with perforated disease (57·5, 40·9 and 35·4 per cent; P < 0·001) and subsequent use of end colostomy (52·2, 24·8 and 18·9 per cent; P < 0·001) in low- compared with middle- and high-HDI settings. The association with colostomy use in low-HDI settings persisted (odds ratio (OR) 3·20, 95 per cent c.i. 1·35 to 7·57; P = 0·008) after risk adjustment for malignant disease (OR 2·34, 1·65 to 3·32; P < 0·001), emergency surgery (OR 4·08, 2·73 to 6·10; P < 0·001), time to operation at least 48 h (OR 1·99, 1·28 to 3·09; P = 0·002) and disease perforation (OR 4·00, 2·81 to 5·69; P < 0·001). Conclusion Global differences existed in the proportion of patients receiving end stomas after left-sided colorectal resection based on income, which went beyond case mix alone

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Corporate philanthropy and community involvement. Analysing companies from France, Germany, the Netherlands and Spain

[EN] This paper analyses the philanthropic behaviour of companies listed on four stock markets: the IBEX 35 (Spain), CAC-40 (France), DAX-30 (Germany) and AEX-25 (Netherlands). A bibliometric method was used to obtain keywords related to corporate philanthropy in literature, while a qualitative content analysis was undertaken to obtain specific philanthropy-related words from company annual reports. 19 groups of words (codes) were defined, indicating the terms used by companies to express corporate philanthropy and community involvement, the forms they use to express such involvement, and the formulas chosen to channel their aid. The word analysis also gave information about the stakeholders that companies take into account when they become involved in community issues. Different hypotheses were stated to determine whether the use of words was related to country, firm size (revenues and employees) or industry. The use of probit regression also allowed us to obtain combinations of these variables that explained the probability of using every term together but not separately. The results indicated that the variables which most affected philanthropic codes were country and revenues. Conversely, the variables which least influenced philanthropic codes were number of employees and industry.Miguel Molina, MBD.; Chirivella González, V.; García Ortega, B. (2016). Corporate philanthropy and community involvement. Analysing companies from France, Germany, the Netherlands and Spain. Quality and Quantity. 50(6):2741-2766. doi:10.1007/s11135-015-0287-9S27412766506Abbott, W.F., Monsen, R.J.: On the measurement of corporate social-responsibility—self-reported disclosures as a method of measuring corporate social involvement. Acad. Manag. J. 22(3), 501–515 (1979)Albareda, L., Lozano, J., Ysa, T.: Public policies on corporate social responsibility: the role of governments in Europe. J. Bus. Ethics 74(4), 391–407 (2007)Amable, B.: The Diversity of Modern Capitalism. Oxford University Press, New York (2003)Arenas, D., Lozano, J.M., Albareda, L.: The role of NGOs in CSR: mutual perceptions among stakeholders. J. Bus. Ethics 88(1), 175–197 (2009)Arendt, S., Brettel, M.: Understanding the influence of corporate social responsibility on corporate identity, image, and firm performance. Manag. Decis. 48(10), 1469–1492 (2010)Ariza-Montes, A., Roldan-Salgueiro, J.L., Leal-Rodriguez, A.: Employee and volunteer an unlikely cocktail? Nonprofit Manag. Leadersh. 25(3), 255–268 (2015)Aßländer, M.S.: Corporate social responsibility as subsidiary co-responsibility: a macroeconomic perspective. J. Bus. Ethics 99(1), 115–128 (2011)Ball, R., Kothari, S.P., Robin, A.: The effect of international institutional factors on properties of accounting earnings. J. Account. Econ. 29(1), 1–51 (2000)Basil, D.Z., Runte, M.S., Easwaramoorthy, M., Barr, C.: Company support for employee volunteering: a national survey of companies in Canada. J. Bus. Ethics 85(2), 387–398 (2009)Basil, D., Runte, M., Basil, M., Usher, J.: Company support for employee volunteerism does size matter? J. Bus. Res. 64(1), 61–66 (2011)Ben Mahjoub, L., Khamoussi, H.: Environmental and social policy and earning persistence. Bus. Strategy Environ. 22(3), 159–172 (2013)Berger, I.E., Cunningham, P.H., Drumwright, M.E.: Identity, identification, and relationship through social alliances. J. Acad. Mark. Sci. 34(2), 128–137 (2006)Berthoin Antal, A., Oppen, M., Sobczak, A.: (Re)discovering the social responsibility of business in Germany. J. Bus. Ethics 89(3), 285–301 (2009)Bigne Alcaniz, E., Chumpitaz Caceres, R., Curras Perez, R.: Alliances between brands and social causes: the influence of company credibility on social responsibility image. J. Bus. Ethics 96(2), 169–186 (2010)Bingham, J.B., Mitchell, B.W., Bishop, D.G., Allen, N.J.: Working for a higher purpose: a theoretical framework for commitment to organization-sponsored causes. Human Resource Management Review 23(2), 174–189 (2013)Blasco, M., Zølner, M.: Corporate social responsibility in Mexico and France. Bus. Soc. 49(2), 216–251 (2010)Bonsón, E., Bednárová, M.: CSR reporting practices of Eurozone companies. Revista de Contabilidad—Spanish. Account. Rev. 18(2), 182–193 (2015)Börner, K., Polley, D.E.: Visual Insights. A Practical Guide to Making Sense of Data. MIT Press, Cambridge (2014)Bornmann, L., Leydesdorff, L.: Topical connections between the institutions within an organisation (institutional co-authorships, direct citation links and co-citations). Scientometrics 102(1), 455–463 (2015)Bowen, F., Newenham-Kahindi, A., Herremans, I.: When suits meet roots: the antecedents and consequences of community engagement strategy. J. Bus. Ethics 95(2), 297–318 (2010)Brammer, S., Millington, A.: The development of corporate charitable contributions in the UK: a stakeholder analysis. J. Manag. Stud. 41(8), 1411–1434 (2004)Brammer, S., Millington, A.: Profit maximisation vs. agency: an analysis of charitable giving by UK firms. Camb. J. Econ. 29(4), 517–534 (2005a)Brammer, S., Millington, A.: Corporate reputation and philanthropy: an empirical analysis. J. Bus. Ethics 61(1), 29–44 (2005b)Branco, M.C., Delgado, C., Sa, M., Sousa, C.: Comparing CSR communication on corporate web sites in Sweden and Spain. Baltic J. Manag. 9(2), 231–250 (2014)Bravo, R., Matute, J., Pina, J.M.: Corporate social responsibility as a vehicle to reveal the corporate identity: a study focused on the websites of spanish financial entities. J. Bus. Ethics 107(2), 129–146 (2012)Brodin Danell, J.A.: Reception of integrative and complementary medicine (ICM) in scientific journals: a citation and co-word analysis. Scientometrics 98(2), 807–821 (2014)Caligiuri, P., Mencin, A., Jiang, K.F.: Win–Win–Win: the influence of company-sponsored volunteerism programs on employees, NGOs, and business units. Pers. Psychol. 66(4), 825–860 (2013)Camilleri, M.A.: Environmental, social and governance disclosures in Europe. Sustain. Account. Manag. Policy J. 6(2), 224–242 (2015)Campbell, D., Moore, G., Metzger, M.: Corporate philanthropy in the UK 1985–2000: some empirical findings. J. Bus. Ethics 39(1/2), 29–41 (2002)Carnevale, C., Mazzuca, M.: Sustainability Reporting and Varieties of Capitalism. Sustain. Dev. 22(6), 361–376 (2014)Carroll, A.B.: A three-dimensional conceptual model of corporate performance. Acad. Manag. Rev. 4(4), 497–505 (1979)Carroll, A.B.: The pyramid of corporate social responsibility: toward the moral management of organizational stakeholders. Bus. Horiz. 34(4), 39–48 (1991)Chen, S., Bouvain, P.: Is corporate responsibility converging? A comparison of corporate responsibility reporting in the USA, UK, Australia, and Germany. J. Bus. Ethics 87(1), 299–317 (2009)Chen, J.C., Patten, D.M., Roberts, R.W.: Corporate charitable contributions: a corporate social performance or legitimacy strategy? J. Bus. Ethics 82(1), 131–144 (2008)Cowan, A., Huang, C.H., Padmanabhan, P., Wang, C.H.: The determinants of foreign giving: an exploratory empirical investigation of US manufacturing firms. Int. Bus. Rev. 22(2), 407–420 (2013)De Gilder, D., Schuyt, T.N.M., Breedijk, M.: Effects of an employee volunteering program on the work force: the ABN-AMRO case. J. Bus. Ethics 61(2), 143–152 (2005)Den Hond, F., De Bakker, F.G.A., Doh, J.: what prompts companies to collaboration with NGOs? Recent evidence from the Netherlands. Bus. Soc. 54(2), 187–228 (2015)De Roeck, K., Marique, G., Stinglhamber, F., Swaen, V.: Understanding employees responses to corporate social responsibility: mediating roles of overall justice and organisational identification. International Journal of Human Resource Management 25(1), 91–112 (2014)Ding, Y., Chowdhury, G.G., Foo, S.: Bibliometric cartography of information retrieval research by using co-word analysis. Inf. Process. Manag. 37(6), 817–842 (2001)Doh, J.P., Guay, T.R.: Corporate social responsibility, public policy, and NGO activism in europe and the United States: an institutional-stakeholder perspective. J. Manag. Stud. 43(1), 47–73 (2006)Elkind, A.B.: Corporate citizenship. American Gas Association Monthly, 51.3, 25 (1969)Fassin, Y., Werner, A., Van Rossem, A., Signori, S., Garriga, E., von Weltzien Hoivik, H., Schlierer, H.J.: CSR and related terms in SME owner–managers’ mental models in six European countries: national context matters. J. Bus. Ethics 128(2), 433–456 (2015)Fifka, M.S.: Corporate citizenship in Germany and the United States—differing perceptions and practices in transatlantic comparison. Bus. Ethics-Eur. Rev. 22(4), 341–356 (2013)Finegold, D., Klossek, A., Nippa, M., Winkler, A.L.: Explaining firm approaches to corporate social responsibility: institutional environment and firm size. Eur. J. Int. Manag. 4(3), 213–233 (2010)Fortanier, F., Kolk, A., Pinkse, J.: Harmonization in CSR reporting MNEs and global CSR standards. Manag. Int. Rev. 51(5), 665–696 (2011)Freeman, I., Hasnaoui, A.: The meaning of corporate social responsibility: the vision of four nations. J. Bus. Ethics 100(3), 419–443 (2011)Frias-Aceituno, J.V., Rodriguez-Ariza, L., Garcia-Sanchez, I.M.: The role of the board in the dissemination of integrated corporate social reporting. Corp. Soc. Responsib. Environ. Manag. 20(4), 219–233 (2013)Gamerschlag, R., Moeller, K., Verbeeten, F.: Determinants of voluntary CSR disclosure: empirical evidence from Germany. RMS 5(2-3), 233–262 (2011)Gan, A.: The impact of public scrutiny on corporate philanthropy. J. Bus. Ethics 69(3), 217–236 (2006)Gatignon-Turnau, A.L., Mignonac, K.: (Mis)Using employee volunteering for public relations: implications for corporate volunteers’ organizational commitment. J. Bus. Res. 68(1), 7–18 (2015)Gautier, A., Pache, A.C.: Research on corporate philanthropy: a review and assessment. J. Bus. Ethics 126(3), 343–369 (2015)George, J.M.: Compassion and capitalism: implications for organizational studies. J. Manag. 40(1), 5–15 (2014)Hall, P.A., Solskice, D.: Varieties of Capitalism. The Institutional Foundations of Comparative Advantage. Oxford University Press, New York (2001)Hansen, E.G., Sextl, M., Reichwald, R.: Managing strategic alliances through a community-enabled balanced scorecard: the Case of Merck Ltd, Thailand. Bus. Strategy Environ. 19(6), 387–399 (2010)Harwood, I., Humby, S., Harwood, A.: On the resilience of corporate social responsibility. Eur. Manag. J. 29(4), 283–290 (2011)Haski-Leventhal, D.: Employee engagement in CSR: the case of payroll giving in Australia. Corp. Soc. Responsib. Environ. Manag. 20(2), 113–128 (2013)Hetherington, J.A.C.: Fact and legal theory—shareholders, managers, and corporate social responsibility. Stanf. Law Rev. 21, 248–292 (1969)House, R.J., Hanges, P.J., Javidan, M., Dorfman, P.W., Gupta, V.: Culture, leadership, and organizations. The Globe Study of 62 Societies. Sage Publications (2004)Johnson, G.: Corporate philanthropy: an analysis of corporate contribution. J. Bus. 39(4), 489–504 (1966)Knudsen, J.S., Moon, J., Slager, R.: Government policies for corporate social responsibility in Europe: a comparative analysis of institutionalisation. Policy Politics 43(1), 81–99 (2013)Legendre, S., Coderre, F.: Determinants of GRI G3 application levels: the case of the fortune global 500. Corp. Soc. Responsib. Environ. Manag. 20(3), 182–192 (2013)Liket, K., Simaens, A.: Battling the devolution in the research on corporate philanthropy. J. Bus. Ethics 126(2), 285–308 (2015)Lin, C.P., Baruch, Y., Shih, W.C.: Corporate social responsibility and team performance: the mediating role of team efficacy and team self-esteem. J. Bus. Ethics 108(2), 167–180 (2012)Lin-Hi, N., Müller, K.: The CSR bottom line: preventing corporate social irresponsibility. J. Bus. Res. 66(10), 1928–1936 (2013)Liu, G., Ko, W.W.: An analysis of cause-related marketing implementation strategies through social alliance: partnership conditions and strategic objectives. J. Bus. Ethics 100(2), 253–281 (2011)Liu, G., Liston-Heyes, C., Ko, W.W.: Employee participation in cause-related marketing strategies: a study of management perceptions from british consumer service industries. J. Bus. Ethics 92(2), 195–210 (2010)Maon, F., Swaen, V., Lindgreen, A.: One vision, different paths: an investigation of corporate social responsibility initiatives in Europe. J. Bus. Ethics (2015). doi: 10.1007/s10551-015-2810-2Marx, J.D.: Corporate philanthropy: what is the strategy? Nonprofit Volunt. Sect. Quart. 28(2), 185–198 (1999)Melin, G., Persson, O.: Studying research collaboration using co-authorships. Scientometrics 36(3), 363–377 (1996)Metzger, L., Nunnenkamp, P., Mahmoud, T.O.: Is corporate aid targeted to poor and deserving countries? A case study of nestles aid allocation. World Dev. 38(3), 228–243 (2010)Miras-Rodriguez, M.D., Carrasco-Gallego, A., Escobar-Perez, B.: Are socially responsible behaviors paid off equally? A cross-cultural analysis. Corp. Soc. Responsib. Environ. Manag. 22(4), 237–256 (2015)Moir, L., Taffler, R.J.: Does corporate philanthropy exist? Business giving to the arts in the UK. J. Bus. Ethics 54(2), 149–161 (2004)Mueller, J., Abfalter, D., Hautz, J., Hutter, K., Matzler, K., Raich, M.: Differences in corporate environmentalism—a comparative analysis of leading US and German companies. European Journal of International Management 5(2), 122–148 (2011)Muthuri, J.N., Matten, D., Moon, J.: Employee volunteering and social capital: contributions to corporate social responsibility. Br. J. Manag. 20(1), 75–89 (2009)Muthuri, J.N., Moon, J., Idemudia, U.: Corporate innovation and sustainable community development in developing countries. Bus. Soc. 51(3), 355–381 (2012)Orlitzky, M., Louche, C., Gond, J.P., Chapple, W.: Unpacking the drivers of corporate social performance: a multilevel, multistakeholder, and multimethod analysis. J. Bus. Ethics (2015). doi: 10.1007/s10551-015-2822-yPajo, K., Lee, L.: Corporate-sponsored volunteering: a work design perspective. J. Bus. Ethics 99(3), 467–482 (2011)Pérez, A., García de los Salmones, M.M., Carlos López, C.: Corporate reputation in the spanish context: an interaction between reporting to stakeholders and industry. J. Bus. Ethics 129(3), 733–746 (2015)Porter, A.L., Kongthon, A., Lui, J.C.: Research profiling: improving the literature review. Scientometrics 53(3), 351–370 (2002)Reimann, F., Ehrgott, M., Kaufmann, L., Carter, C.R.: Local stakeholders and local legitimacy: MNEs social strategies in emerging economies. J. Int. Manag. 18(1), 1–17 (2012)Reverte, C.: Determinants of corporate social responsibility disclosure ratings by spanish listed firms. J. Bus. Ethics 88(2), 351–366 (2009)Sapir, A.: Globalization and the reform of European social models. Journal of Common Market Studies 44(2), 369–390 (2006)Schneider, M.R., Paunescu, M.: Changing varieties of capitalism and revealed comparative advantages from 1990 to 2005: a test of the Hall and Soskice claims. Socio-Economic Review 10(4), 731–753 (2012)Schreier, M.: Qualitative content analyses. In: Flick, U. (ed.) SAGE Handbook of Qualitative Data Analysis, pp. 170–183. SAGE Publications LTD, London (2013)Searcy, C., Buslovich, R.: Corporate perspectives on the development and use of sustainability reports. J. Bus. Ethics 121(2), 149–169 (2014)Sison, A.J.G.: From CSR to corporate citizenship: Anglo-American and continental European perspectives. J. Bus. Ethics 89(3), 235–246 (2009)Slack, R.E., Corlett, S., Morris, R.: Exploring employee engagement with (corporate) social responsibility: a social exchange perspective on organisational participation. J. Bus. Ethics 127(3), 537–548 (2015)Torres, A., Bijmolt, T.H.A., Tribo, J.A., Verhoef, P.: Generating global brand equity through corporate social responsibility to key stakeholders. Int. J. Res. Mark. 29(1), 13–24 (2012)Valor Martinez, C.: Social alliances for fundraising: how Spanish nonprofits are hedging the risks. J. Bus. Ethics 47(3), 209–222 (2003)Van der Voort, J.M., Glac, K., Meijs, L.C.P.M.: “Managing” corporate community involvement. J. Bus. Ethics 90(3), 311–329 (2009)Vazquez-Carrasco, R., Lopez-Perez, M.E.: Small & medium-sized enterprises and corporate social responsibility: a systematic review of the literature. Qual. Quant. 47(6), 3205–3218 (2013)Young, S., Marais, M.: A multi-level perspective of CSR reporting: the implications of National Institutions and Industry Risk Characteristics. Corporate Governance: An International Review 20(5), 432–450 (2012

Risk categorization using New American College of Cardiology/American Heart Association guidelines for cholesterol management and its relation to alirocumab treatment following acute coronary syndromes

Background: The 2018 US cholesterol management guidelines recommend additional lipid-lowering therapies for secondary prevention in patients with low-density lipoprotein cholesterol ≥70 mg/dL or non−high-density lipoprotein cholesterol ≥100 mg/dL despite maximum tolerated statin therapy. Such patients are considered at very high risk (VHR) based on a history of >1 major atherosclerotic cardiovascular disease (ASCVD) event or a single ASCVD event and multiple high-risk conditions. We investigated the association of US guideline-defined risk categories with the occurrence of ischemic events after acute coronary syndrome and reduction of those events by alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor. Methods: In the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), patients with recent acute coronary syndrome and residual dyslipidemia despite optimal statin therapy were randomly assigned to alirocumab or placebo. The primary trial outcome (major adverse cardiovascular events, ie, coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina) was examined according to American College of Cardiology/American Heart Association risk category. Results: Of 18 924 participants followed for a median of 2.8 years, 11 935 (63.1%) were classified as VHR: 4450 (37.3%) had multiple prior ASCVD events and 7485 (62.7%) had 1 major ASCVD event and multiple high-risk conditions. Major adverse cardiovascular events occurred in 14.4% of placebo-treated patients at VHR versus 5.6% of those not at VHR. In the VHR category, major adverse cardiovascular events occurred in 20.4% with multiple prior ASCVD events versus 10.7% with 1 ASCVD event and multiple high-risk conditions. Alirocumab was associated with consistent relative risk reductions in both risk categories (hazard ratio=0.84 for VHR; hazard ratio=0.86 for not VHR; Pinteraction=0.820) and by stratification within the VHR group (hazard ratio=0.86 for multiple prior ASCVD events; hazard ratio=0.82 for 1 major ASCVD event and multiple high-risk conditions; Pinteraction=0.672). The absolute risk reduction for major adverse cardiovascular events with alirocumab was numerically greater (but not statistically different) in the VHR group versus those not at VHR (2.1% versus 0.8%; Pinteraction=0.095) and among patients at VHR with multiple prior ASCVD events versus a single prior ASCVD event (2.4% versus 1.8%; Pinteraction=0.661). Conclusions: The US guideline criteria identify patients with recent acute coronary syndrome and dyslipidemia who are at VHR for recurrent ischemic events and who may derive a larger absolute benefit from treatment with alirocumab. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402